Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Category: Therapies, Treatments, and Procedures
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]
Where Are We Now?
A Summary of the Past 30 Years of Low Vision Research and Development (An update presented to the International Low Vision Support Group by Director Dan Roberts) Macular Degeneration Support’s International Low Vision Support Group will soon celebrate its 30th year as a leading outreach to people affected by macular degeneration and other diseases leading [Read More]
First Human Eyeball Transplant Accomplished
Eye specialists at New York University Langone Health have announced success with the first transplantation of a complete human eyeball. High-voltage lineman Aaron James, 46, lost his eye in an electrocution accident on June 10, 2021. His multiple surgeries included a partial face transplant, during which the surgeons decided to also replace his eye. This [Read More]
IZERVAY™, is the Second Treatment Approved by the FDA for Geographic Atrophy
IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc. announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]